Jazz Pharmaceuticals plc JAZZ

Set alert

Price alert · JAZZ

All alert types
214.44 USD -1.54 -0.71%

At close · Nov 2

211.05 -3.39 -1.58%

After hours · Nov 2, 6:16 PM ET

Bid
214.38 × 2
Ask
215.01 × 2
213.81 Day range 218.36
128.80 52-week range 266.38
YTD
+26.14%
1 year
+55.80%
Open
215.84
Prev close
215.98
Mkt cap
13.92B
Vol
1.04M
Avg vol
899.55K
EPS
14.59
P/E
14.70
Div yield
0.00%
More statistics
Low
213.81
High
218.36
Forward P/E
8.51
Beta
0.37
Short ratio
6.86
Inst. own
103.88%
Dividend
0.00
Ex-div date
Earnings
Nov 2, 2026
50-d avg
231.96
200-d avg
216.63
1y target
295.36

1m chart

Chart tools
Interval

Built from the cached one-day intraday bars.

Events in this range
  • Nov 2, 2026Earnings: —; estimate -4.05; surprise —%
Signals (99)
NameTimeAgo
RSI: OversoldNov 2, 3:58 PM6 hours ago
SMA: BearishNov 2, 3:55 PM6 hours ago
MACD: Sell SignalNov 2, 3:55 PM6 hours ago
SMA: BullishNov 2, 3:53 PM6 hours ago
MACD: Buy SignalNov 2, 3:53 PM6 hours ago
SMA: BearishNov 2, 3:49 PM6 hours ago
SMA: BullishNov 2, 3:48 PM6 hours ago
RSI: OversoldNov 2, 3:40 PM6 hours ago
SMA: BearishNov 2, 3:20 PM6 hours ago
SMA: BearishNov 2, 3:20 PM6 hours ago
SMA: BullishNov 2, 3:19 PM6 hours ago
SMA: BearishNov 2, 3:18 PM6 hours ago
SMA: BullishNov 2, 3:13 PM6 hours ago
SMA: BearishNov 2, 3:10 PM6 hours ago
MACD: Sell SignalNov 2, 3:10 PM6 hours ago
MACD: Buy SignalNov 2, 3:09 PM6 hours ago
RSI: OverboughtNov 2, 3:08 PM6 hours ago
MACD: Sell SignalNov 2, 3:07 PM6 hours ago
RSI: OverboughtNov 2, 3:01 PM7 hours ago
RSI: OverboughtNov 2, 2:57 PM7 hours ago
RSI: OverboughtNov 2, 2:41 PM7 hours ago
SMA: BullishNov 2, 2:39 PM7 hours ago
SMA: BullishNov 2, 2:39 PM7 hours ago
MACD: Buy SignalNov 2, 2:39 PM7 hours ago
MACD: Sell SignalNov 2, 2:38 PM7 hours ago
SMA: BearishNov 2, 2:33 PM7 hours ago
SMA: BearishNov 2, 2:33 PM7 hours ago
MACD: Buy SignalNov 2, 2:28 PM7 hours ago
SMA: BullishNov 2, 2:24 PM7 hours ago
SMA: BullishNov 2, 2:24 PM7 hours ago
MACD: Sell SignalNov 2, 2:18 PM7 hours ago
SMA: BearishNov 2, 2:17 PM7 hours ago
SMA: BullishNov 2, 2:15 PM7 hours ago
SMA: BearishNov 2, 2:12 PM7 hours ago
SMA: BullishNov 2, 2:00 PM8 hours ago
SMA: BearishNov 2, 1:59 PM8 hours ago
SMA: BullishNov 2, 1:55 PM8 hours ago
MACD: Buy SignalNov 2, 1:51 PM8 hours ago
SMA: BullishNov 2, 1:50 PM8 hours ago
SMA: BearishNov 2, 1:42 PM8 hours ago
SMA: BullishNov 2, 1:41 PM8 hours ago
SMA: BearishNov 2, 1:21 PM8 hours ago
SMA: BearishNov 2, 1:21 PM8 hours ago
SMA: BullishNov 2, 1:20 PM8 hours ago
SMA: BullishNov 2, 1:20 PM8 hours ago
MACD: Sell SignalNov 2, 1:17 PM8 hours ago
SMA: BearishNov 2, 1:13 PM8 hours ago
SMA: BearishNov 2, 1:13 PM8 hours ago
SMA: BullishNov 2, 1:11 PM8 hours ago
SMA: BearishNov 2, 1:09 PM8 hours ago
MACD: Buy SignalNov 2, 1:07 PM8 hours ago
SMA: BullishNov 2, 1:06 PM8 hours ago
SMA: BullishNov 2, 1:05 PM8 hours ago
SMA: BearishNov 2, 12:52 PM9 hours ago
MACD: Sell SignalNov 2, 12:44 PM9 hours ago
SMA: BearishNov 2, 12:43 PM9 hours ago
RSI: OverboughtNov 2, 12:28 PM9 hours ago
MACD: Buy SignalNov 2, 12:18 PM9 hours ago
SMA: BullishNov 2, 12:14 PM9 hours ago
SMA: BearishNov 2, 12:12 PM9 hours ago
SMA: BullishNov 2, 12:11 PM9 hours ago
SMA: BearishNov 2, 12:08 PM9 hours ago
SMA: BullishNov 2, 12:07 PM9 hours ago
MACD: Sell SignalNov 2, 12:05 PM9 hours ago
SMA: BullishNov 2, 12:01 PM10 hours ago
SMA: BearishNov 2, 12:00 PM10 hours ago
SMA: BullishNov 2, 11:51 AM10 hours ago
SMA: BearishNov 2, 11:50 AM10 hours ago
SMA: BullishNov 2, 11:31 AM10 hours ago
MACD: Buy SignalNov 2, 11:21 AM10 hours ago
SMA: BullishNov 2, 11:19 AM10 hours ago
RSI: OversoldNov 2, 11:16 AM10 hours ago
SMA: BearishNov 2, 10:53 AM11 hours ago
MACD: Sell SignalNov 2, 10:53 AM11 hours ago
SMA: BearishNov 2, 10:50 AM11 hours ago
SMA: BullishNov 2, 10:49 AM11 hours ago
SMA: BearishNov 2, 10:48 AM11 hours ago
SMA: BullishNov 2, 10:45 AM11 hours ago
SMA: BearishNov 2, 10:44 AM11 hours ago
SMA: BullishNov 2, 10:39 AM11 hours ago
MACD: Buy SignalNov 2, 10:39 AM11 hours ago
SMA: BullishNov 2, 10:36 AM11 hours ago
SMA: BearishNov 2, 10:33 AM11 hours ago
MACD: Sell SignalNov 2, 10:33 AM11 hours ago
SMA: BullishNov 2, 10:31 AM11 hours ago
SMA: BearishNov 2, 10:30 AM11 hours ago
SMA: BearishNov 2, 10:30 AM11 hours ago
SMA: BullishNov 2, 10:25 AM11 hours ago
SMA: BullishNov 2, 10:20 AM11 hours ago
SMA: BearishNov 2, 10:19 AM11 hours ago
SMA: BearishNov 2, 10:17 AM11 hours ago
SMA: BullishNov 2, 10:16 AM11 hours ago
SMA: BullishNov 2, 10:08 AM11 hours ago
SMA: BearishNov 2, 9:58 AM12 hours ago
SMA: BullishNov 2, 9:56 AM12 hours ago
SMA: BearishNov 2, 9:54 AM12 hours ago
SMA: BullishNov 2, 9:50 AM12 hours ago
SMA: BearishNov 2, 9:48 AM12 hours ago
SMA: BullishNov 2, 9:47 AM12 hours ago

Key statistics

Market cap
13.92B
Enterprise value
16.23B
Trailing P/E
14.70
Forward P/E
8.51
PEG ratio
0.96
Price / sales
3.03
Price / book
2.89
EPS (TTM)
14.59
Beta
0.37
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
20.45%
Revenue (TTM)
4.60B
Revenue growth
15.50%
Free cash flow
1.43B
Total cash
2.20B
Total debt
4.41B
Return on equity
22.11%
Shares outstanding
64.91M
Short % of float
9.30%
50-day average
231.96
200-day average
216.63

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 295.36 +37.7% upside
Target (low)
225.00
Target (mean)
295.36
Target (high)
337.00
Ratings (0m) 22 20 buy · 2 hold · 0 sell
  • Strong buy7
  • Buy13
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Nov 2, 2026

Expected Nov 2, 2026. Consensus EPS estimate -2.38.

Earnings history

Financials — quick view

All financials
JAZZ Revenue — quarterly 1.21B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
JAZZ Net income — quarterly 192.80M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
JAZZ EPS — quarterly 3.05
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

JAZZ recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 2, 2026Sep 30, 2026-4.05———
Aug 3, 2026Jun 30, 20266.185.71-0.47-7.61%
May 5, 2026Mar 31, 20264.646.34+1.70+36.64%
Feb 24, 2026Dec 31, 20256.526.64+0.12+1.84%
Nov 5, 2025Sep 30, 20255.958.13+2.18+36.64%
Aug 5, 2025Jun 30, 2025-6.12-8.25-2.13-34.80%

Upgrades / downgrades

JAZZ analyst upgrades and downgrades
DateFirmActionFromTo
Oct 28, 2026JP MorganmainOverweightOverweight
Oct 21, 2026Morgan StanleymainOverweightOverweight
Oct 8, 2026RBC CapitalmainOutperformOutperform
Oct 7, 2026Truist SecuritiesmainBuyBuy
Sep 30, 2026Citigroupinit—Buy
Sep 11, 2026UBSmainBuyBuy

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Sector
Healthcare
Industry
Biotechnology
Country
Ireland

News

Your note

Sign in to keep a note on JAZZ — it syncs with the Stock Master app.

Insider holders

JAZZ insider holders
InsiderRelationLatest transactionDateShares held
COZADD BRUCE CDirectorSaleSep 30, 2026345,875
ENRIGHT PATRICK G.DirectorStock Award(Grant)Aug 4, 202622,984
GALA RENEE DChief Executive OfficerSaleOct 5, 2026141,394
HENDERSON MARY ELIZABETHOfficerSaleFeb 25, 202628,728
IANNONE ROBERTOfficerConversion of Exercise of derivative securityAug 26, 202665,686
JOHNSON PHILIP LChief Financial OfficerStock Award(Grant)Feb 25, 202662,223

Institution ownership

JAZZ institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.19%5,968,6031.28BJun 29, 2026
FMR, LLC7.10%4,609,326988.42MJun 29, 2026
Vanguard Portfolio Management LLC4.68%3,036,213651.09MJun 29, 2026
Vanguard Capital Management LLC4.20%2,729,650585.35MJun 29, 2026
Capital World Investors4.16%2,697,610578.48MJun 29, 2026
LSV Asset Management3.50%2,275,145487.88MJun 29, 2026

Fund ownership

JAZZ fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%2,312,286495.85MSep 29, 2026
AMERICAN FUNDS FUNDAMENTAL INVESTORS2.93%1,900,000407.44MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.92%1,892,522405.83MJun 29, 2026
Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund2.41%1,561,563334.86MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.11%1,366,767293.09MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund1.33%865,937185.69MJun 29, 2026